{
    "nctId": "NCT00662103",
    "briefTitle": "Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors",
    "officialTitle": "Comparison of Aerobic and Resistance Exercise in Older Breast Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer Survivor, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Psychosocial Effects of Cancer and Its Treatment",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 115,
    "primaryOutcomeMeasure": "Comparison of the effects of aerobic exercise vs flexibility and relaxation training (control) on fatigue, aerobic capacity, functioning, and health outcomes as measured at baseline and at 3, 6, 12, and 18 months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer\n\n  * Stage 0-III disease\n* Completed chemotherapy or radiotherapy \\> 2 years ago\n* Is not a regular participant in moderate aerobic exercise (i.e., jogging, swimming) or moderate resistance exercise (\\> 3 times/week for \u2265 30 minutes/session) OR in vigorous aerobic or resistance exercise (\\> 3 times/week for \u2265 20 minutes/session)\n* No stage IV breast cancer\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Has obtained medical clearance to participate in study exercise programs\n* No cognitive difficulties that would preclude answering the survey questions, participating in the performance tests, or giving informed consent\n* No medical condition or movement or neurological disorder that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the Principal Investigator\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No concurrent medication that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the Principal Investigator\n* Concurrent hormonal therapy (e.g., selective estrogen receptor modulator (SERM) or aromatase inhibitor) for breast cancer allowed",
    "sex": "FEMALE",
    "minimumAge": "65 Years",
    "stdAges": "OLDER_ADULT"
}